BiotechTube

Recombinant Vesicular Stomatitis Vaccine for Ebola (rVSV∆G-ZEBOV-GP)

Phase 2Active
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Ebola Virus Disease

Conditions

Ebola Virus Disease

Trial Timeline

Aug 6, 2024 → Aug 31, 2027

NCT ID
NCT06100913

About Recombinant Vesicular Stomatitis Vaccine for Ebola (rVSV∆G-ZEBOV-GP)

Recombinant Vesicular Stomatitis Vaccine for Ebola (rVSV∆G-ZEBOV-GP) is a phase 2 stage product being developed by Merck for Ebola Virus Disease. The current trial status is active. This product is registered under clinical trial identifier NCT06100913. Target conditions include Ebola Virus Disease.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT06100913Phase 2Active

Competing Products

20 competing products in Ebola Virus Disease

See all competitors
ProductCompanyStageHype Score
Ad26.ZEBOV vaccineJohnson & JohnsonPhase 2
52
rVSVΔG-ZEBOV-GP, V920 + Chikenpox or Varicella vaccine (VARILRIX)MerckPhase 1/2
41
V920 VaccineMerckPhase 1
33
rVSVDG-ZEBOV-GP Ebola Virus Vaccine (ERVEBO)MerckApproved
85
V920 (rVSVΔG-ZEBOV-GP) Ebola Virus VaccineMerckPhase 2
52
V920MerckPhase 1
33
V920 Consistency Lot A + V920 Consistency Lot B + V920 Consistency Lot C + V920 High-dose Lot + Placebo to V920MerckPhase 3
77
BioNTech - Pfizer COVID-19 vaccine + 1mL saline solution + rVSV∆G-ZEBOV-GPMerckApproved
85
V920MerckPhase 1
33
GS-5734Gilead SciencesPhase 2
51
REGN3470-3471-3479Regeneron PharmaceuticalsPre-clinical
22
Ervebo + InmazebRegeneron PharmaceuticalsPhase 2
51
AVI-7537United TherapeuticsPhase 1
30
Placebo + AVI-6002United TherapeuticsPhase 1
30
Ad26.ZEBOV + MVA-BN-FiloBavarian NordicPhase 3
74
CMX001Jazz PharmaceuticalsPhase 2
49
BrincidofovirJazz PharmaceuticalsPhase 2
49
cAd3-Marburg + cAd3-EBO-SICON plc.Phase 1
30
Base Dose EBOV GP Vaccine + 2x Base Dose EBOV GP Vaccine + 4x Base Dose EBOV GP Vaccine + 8x Base Dose EBOV GP Vaccine + Placebo + Matrix-M AdjuvantNovavaxPhase 1
28
TKM-100802 for Injection + PlaceboArbutus BiopharmaPhase 1
28

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85